Ligia Carolina Facin: Investigating a Novel Therapeutic Strategy for ATTR-CM
Ligia Carolina Facin, Fellowship in Cardiac Amyloidosis at Ensino InCor, Cardio-Oncology Resident at Heart Institute, University of São Paulo (FMUSP), shared a post on LinkedIn:
“It was a great privilege to participate in the CLEOPATTRA Investigators’ Meeting, an international clinical trial investigating a novel therapeutic strategy for transthyretin amyloid cardiomyopathy (ATTR-CM).
Over the past few years, we have witnessed remarkable advances in the treatment of ATTR-CM.
Now, a new frontier is being explored: therapies aimed at removing amyloid deposits already present in cardiac tissue, with the potential to further transform the course of the disease.
Being part of a study investigating this innovative therapeutic approach is a unique opportunity to contribute to the evidence that may shape the future of cardiac amyloidosis treatment.
Science, international collaboration, and clinical research opening new perspectives for our patients.”

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: Towards Sustainable Anticoagulation
-
Nov 18, 2026, 13:33Breaking the Silence on Women and Girls with Bleeding Disorders – EHC
-
Nov 18, 2026, 13:32Maria Elisa Mancuso: Next-Generation Protein Therapies in Hemophilia
-
Nov 18, 2026, 13:25Maia Meier: Advocating for Women and Girls with Bleeding Disorders
-
Nov 18, 2026, 13:19Sjoerd Fabian Koopman: Exploring Tissue Distribution of Extended Half-Life Factor IX Concentrates
-
Nov 18, 2026, 13:16Ifeanyichukwu Ifechidere: Choosing Between Clot-Based and Chromogenic Coagulation Assays
-
Nov 18, 2026, 13:06Saurabh Mehta: Daily Iron Supplementation in Children and Adolescents